|
NEWS CENTER
DOR
BioPharma 2005 News Archive.
Dec 9 , 2005
DOR
BioPharma Maintains AMEX Listing.
Nov
29, 2005
DOR
BioPharma Receives Notice from AMEX that it is Out of
Compliance with Continued Listing Standards.
Nov
17, 2005
DOR
BioPharma and DowpharmaSM Complete Feasibility Study
for Production of BT-VACCTM, DOR's Recombinant Botulinum
Vaccine.
Nov
15, 2005
DOR
BioPharma Plans FDA NDA and European MAA Filing Strategy
for orBec®.
Nov
14, 2005
DOR
BioPharma, Inc. Reports Third Quarter 2005 Financial
Results and Reviews Recent Achievements Conference call
scheduled for November 16th 10AM EST.
Nov
7, 2005
DOR
BioPharma to Present at the Rodman & Renshaw Techvest
7th Annual Healthcare Conference.
Nov
2, 2005
DOR
BioPharma Executes Letter of Intent for Acquisition
of Gastrotech Pharma. Acquisition Bolsters Biotherapeutics
Pipeline.
Nov
1, 2005
DOR
BioPharma Receives Notice of Delisting from American
Stock Exchange. Company to Continue to Negotiate Potential
Compliance-Achieving Transactions During 45 Day Appeal
Period.
Oct
14, 2005
DOR
BioPharma Provides Update on Programs and Corporate
Matters.
Aug
15, 2005
DOR
BioPharma Reports Second Quarter 2005 Financial Results
and Reviews Achievements.
July
26, 2005
DOR
BioPharma and Dowpharma Enter into a Joint Development
Agreement for BT-VACCTM, DOR’s Oral Vaccine Against
Botulinum Toxin Poisoning.
July
20, 2005
DOR
BioPharma and Cambrex Achieve Milestone in the Development
and Manufacture of RiVax™ - DOR and Cambrex Extend Their
Manufacturing Agreement -
July
13, 2005
DOR
BioPharma’s Compliance Plan Period Extended by AMEX.
June
15, 2005
DOR
BioPharma, Inc. Announces Positive Interim Results from
Phase I Clinical Trial of RiVax™, its Ricin Toxin Vaccine.
June
13, 2005
DOR
BioPharma to Present at the Rodman & Renshaw Techvest
2nd Annual Security and Connectivity Conference.
May
16, 2005
DOR
BioPharma, Inc. Reports First Quarter 2005 Financial
Results and Reviews Achievements.
May
4, 2005
DOR
BioPharma Appoints T. Jerome Madison to Board of Directors.
May
4, 2005
DOR
BioPharma to Present at the Rodman & Renshaw Techvest
2nd Annual Global Healthcare Conference.
April
20, 2005
DOR
BioPharma to File NDA for orBec®. .
April
15, 2005
DOR’s
Abstract Describing orBec® Phase III Clinical Trial
Results Selected for Presentation at the Annual Meeting
of the American Association of Cancer Research.
April
14, 2005
DOR
BioPharma’s Gregory Davenport to Participate as Panel
Member in Bio-Chem Defense Vaccines and Therapeutics
Conference.
March
14, 2005
DOR
BioPharma Reports Fourth Quarter and Year End Financial
Results and Accomplishments for 2004.
March
11, 2005
George
A. Robertson, Ph.D. Joins DOR BioPharma as Vice President
of Research and Development.BioDefense expert will lead
DOR’s Botulinum vaccine and antidote programs.
March
9, 2005
DOR
BioPharma to Present at the Valuerich Small-Cap Financial
Expo Conference.
March
1, 2005
DOR
BioPharma to Present at the New York Society of Security
Analysts’ Homeland Security Industry Conference.
February
16, 2005
DOR
BioPharma Initiates New Botulinum Toxin Therapeutic
Program. Complements DOR's BT-VACC ``Oral Botulinum
Toxin Vaccine'' Program.
February
9, 2005
DOR
BioPharma Closes $3.77 Million Private Equity Financing
With Institutional Investors.
February
7, 2005
DOR
Biopharma reports initiations of dosing of Ricin Vaccine
(RIVAXTM) in phase I Clinical trial. First human clinical
trials of a Ricin toxin vaccine.
February
3, 2005
DOR
BioPharma Announces Private Equity Financing of $3.77
Million With Institutional Investors. Financing Provides
Working Capital for BioDefense Products and Potential
orBec® NDA.
January
25, 2005
DOR
BioPharma's Compliance Plan accepted by AMEX
January
7, 2005
DOR
BioPharma and Cambrex enter into a development and manufacturing
process agreement for Rivax™
|
